NCT01684800已完成2 期
A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 178
- 试验地点
- 36
- 主要终点
- Change from baseline in mean number of nocturnal voids
研究概览
简要总结
The purpose of the study is to investigate the efficacy and safety of two different dose levels of desmopressin orally disintegrating tablets against placebo for the treatment of nocturia in adult women during 12 weeks treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Has given written consent prior to any trial-related activity is performed.
- •Female sex, aged 20 years or older.
- •At least 2 nocturnal voids every night in a consecutive 3-day period as documented in the diary during the screening period.
- •Has given agreement about contraception during the trial.
排除标准
- •Showing symptoms of any of the following diseases: Interstitial cystitis; Overactive bladder, defined as >6 daytime voids,≥1 urgency episode and ≥1 urge urinary incontinence episode per 24 hours as documented in the 3-day diary period; Severe stress urinary incontinence.
- •Psychogenic or habitual polydipsia.
- •Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention.
- •A history of urologic malignancies or a history of cancer which has not been in remission for the last 5 years.
- •Genito-urinary tract pathology.
- •Neurogenic detrusor activity.
- •Suspicion or evidence of heart failure.
- •Uncontrolled hypertension.
- •Uncontrolled diabetes mellitus.
- •Hepatobiliary diseases: Aspartate aminotransferase >80 U/L or alanine aminotransferase >90 U/L; Total bilirubin >1.5 mg/dL.
- •Renal insufficiency: Serum creatinine level >0.82 mg/dL; Estimated glomerular filtration rate <50 mL/min.
- •Hyponatraemia: Serum sodium level <135 mEq/L.
- •Central or nephrogenic diabetes insipidus.
- •Syndrome of inappropriate antidiuretic hormone.
- •Obstructive sleep apnea.
- •Previous desmopressin treatment.
- •Treatment with another investigational product within the past 3 months.
- •Concomitant treatment with any prohibited medication.
- •Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial.
- •Alcohol or substance abuse.
- •A job or lifestyle that may interfere with regular night-time sleep.
- •A mental condition, lack of decision-making ability, dementia, a speech handicap, or any other reason which, in the judgement of the investigator (sub-investigator), would impair the participation in the trial.
研究组 & 干预措施
A. Desmopressin 10 microgram
Active Comparator
干预措施: A. Desmopressin 10 microgram (Drug)
结局指标
主要结局
Change from baseline in mean number of nocturnal voids
时间窗: During 12 weeks
次要结局
- Change from baseline in mean time to first void(1, 4, 8 and 12 weeks)
- Responder status (33% reduction in nocturnal voids)(1, 4, 8 and 12 weeks)
- Change from baseline in mean number of nocturnal voids(1, 4, 8 and 12 weeks)
- Change from baseline in mean nocturnal urine volume(1, 4, 8 and 12 weeks)
- Change from baseline in nocturnal polyuria index(1, 4, 8 and 12 weeks)
- Change from baseline in the effect on sleep disturbance(1, 4, 8 and 12 weeks)
- Change from baseline in the impact on quality of life(12 weeks)
- Adverse events, changes from baseline in serum sodium level, laboratory values(During 12 weeks)
研究者
研究点 (36)
Loading locations...
相似试验
已完成
2 期
Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult MenNocturiaNCT01694498Ferring Pharmaceuticals183
已完成
3 期
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological ConditionsChronic Troublesome SialorrheaPost-strokeTraumatic Brain InjuryParkinson's DiseaseNCT02091739Merz Pharmaceuticals GmbH184
已完成
3 期
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.Psychotic DisorderSchizoaffective DisorderNCT00397033Johnson & Johnson Pharmaceutical Research & Development, L.L.C.316
已完成
3 期
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) TrialDiabetes Mellitus, Type 2NCT01081834Janssen Research & Development, LLC678
已完成
2 期
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque PsoriasisPlaque PsoriasisNCT01230138Forward-Pharma GmbH252